Quantcast
Last updated on April 23, 2014 at 15:59 EDT

Latest Erythropoiesis-stimulating agents Stories

2014-03-28 12:26:15

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" [http://www.researchandmarkets.com/research/8zbxmj/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by...

2014-03-11 23:00:21

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store. Dallas, TX (PRWEB) March 12, 2014 Epoetin alfa refers to erythropoietin (EPO), a hormonelike substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization. The ratio between EPO used in renal dialysis and in...

2014-01-28 12:30:02

The CKD Market Will Decline Through 2017, Due to Genericization of Expensive Agents and Reimbursement Constraints in the U.S., According to Findings from Decision Resources Group BURLINGTON, Mass., Jan. 28, 2014 /PRNewswire/ -- Decision Resources Group finds that, after an initial decline driven by generic and biosimilar competition in the G7 markets and changes in reimbursement practices in the United States, the total chronic kidney disease (CKD) market will return to growth, achieving...

2013-10-01 12:29:39

Surveyed Nephrologists State that 25 Percent of CKD-ND Patients are Likely Candidates for Recently Approved Injectafer, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed nephrologists, familiarity with Roche's Mircera, is low, but is still second highest among six late-stage renal therapies...

2013-07-18 10:27:16

In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published July 17 in the Journal of the National Cancer Institute. To investigate the safety and...

2013-06-03 16:26:40

-- Post-marketing study, presented at ASCO, included more than 2,300 patients -- LAKE FOREST, Ill., June 3, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing study of the company's European biosimilar epoetin, Retacrit(TM). This prospective, observational study met the primary endpoint, as defined by hemoglobin treatment response, in the management of...

2013-05-21 16:27:13

BALTIMORE, May 21, 2013 /PRNewswire/ -- U.S. Renal Care has agreed to pay $7.3 million to the federal government to settle a whistleblower lawsuit brought by a nurse that alleged a company U.S. Renal Care acquired, Dialysis Corporation of America (DCA), overcharged Medicare for years for an anemia drug used to treat dialysis patients. The "qui tam" (whistleblower) lawsuit alleged that DCA was billing Medicare and other government healthcare programs for more Epogen than was actually used....

2013-03-11 15:08:13

Phase 3 findings published in NEJM provide answers about treatment with darbepoetin alfa Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients —darbepoetin alfa — does not improve patients' health, nor does it reduce their risk of death from heart failure. Results of the international study were presented at the American College of Cardiology's annual meeting in San...

2013-02-28 08:30:00

NEW YORK, February 28, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Endo Health Solutions Inc (NASDAQ: ENDP), Actavis Inc (NYSE: ACT), Mylan Inc. (NASDAQ: MYL), Elan Corporation, plc (NYSE: ELN) and Amgen, Inc. (NASDAQ: AMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Endo Health Solutions Inc Research Report Endo...

Recall Notice Issued For Anemia Drug Omontys
2013-02-25 05:22:08

redOrbit Staff & Wire Reports - Your Universe Online Two pharmaceutical companies have issued a recall of their anemia drug Omontys after receiving reports that some kidney dialysis patients had suffered severe allergic reactions after taking the medication. According to the Associated Press (AP), California-based Affymax Inc. and Illinois-based Takeda Pharmaceutical Co. said some of the more than 25,000 patients who had received the drug had experienced adverse effects afterwards,...